Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-hydroxybutyrate plus operant behavioral pain therapy in fibromyalgia syndrome
2005-002475-32Phase 3Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sodium oxybate in fibromyalgia (FM), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Pain reduction by consultation frequency and MPI score over 12 months. Started May 2006; status: terminated.
02
Drugs
sodium oxybate
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2005-002475-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002475-32.